Immunogenic and Protective Properties of Recombinant Hemagglutinin of Influenza A (H5N8) Virus.
CHO-K1
immunogenicity
influenza A (H5N8) virus
protection
recombinant hemagglutinin
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
30
11
2023
revised:
23
01
2024
accepted:
27
01
2024
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
24
2
2024
Statut:
epublish
Résumé
In this study, we characterized recombinant hemagglutinin (HA) of influenza A (H5N8) virus produced in Chinese hamster ovary cells (CHO-K1s). Immunochemical analysis showed that the recombinant hemagglutinin was recognized by the serum of ferrets infected with influenza A (H5N8) virus, indicating that its antigenic properties were retained. Two groups of Balb/c mice were immunized with intramuscular injection of recombinant hemagglutinin or propiolactone inactivated A/Astrakhan/3212/2020 (H5N8) influenza virus. The results demonstrated that both immunogens induced a specific antibody response as determined by ELISA. Virus neutralization assay revealed that sera of immunized animals were able to neutralize A/turkey/Stavropol/320-01/2020 (H5N8) influenza virus-the average neutralizing titer was 2560. Immunization with both recombinant HA/H5 hemagglutinin and inactivated virus gave 100% protection against lethal H5N8 virus challenge. This study shows that recombinant HA (H5N8) protein may be a useful antigen candidate for developing subunit vaccines against influenza A (H5N8) virus with suitable immunogenicity and protective efficacy.
Identifiants
pubmed: 38400127
pii: vaccines12020143
doi: 10.3390/vaccines12020143
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the Ministry of Science and Higher Education of the Russian Federation in the implementation of the research program "Use of synchrotron radiation for virologic research" within the framework of the Federal Scientific and Technical Program for the Develop
ID : Agreement No. 075-15-2021-1355 (12 October 2021)